

Drug	Plasma concentration (μM)	Reference
Regorafenib	8,1	Liston & Davis (2017) (Liston & Davis, 2017)
Birinapant	1,0	Zhu <i>et al.</i> (2018) (Zhu <i>et al.</i> , 2018)
Lapatinib	4,2	Liston & Davis (2017) (Liston & Davis, 2017)
Navitoclax	6,6	Wilson <i>et al.</i> (2010) (Wilson <i>et al.</i> , 2010)
Entrectinib	4,0	Meneses-lorente <i>et al.</i> (2021) (Meneses-Lorente <i>et al.</i> , 2021)
Linsitinib	6,9	Macaulay <i>et al.</i> (2017) (Macaulay <i>et al.</i> , 2017)
Crizotinib	0,9	Liston & Davis (2017) (Liston & Davis, 2017)
Dovitinib	0,6	Kang <i>et al.</i> (2013) (Kang <i>et al.</i> , 2013)
Ponatinib	0,1	Liston & Davis (2017) (Liston & Davis, 2017)
Sorafenib	20,1	Liston & Davis (2017) (Liston & Davis, 2017)
Romidepsin	0,7	Liston & Davis (2017) (Liston & Davis, 2017)
Vandetanib	2,2	Liston & Davis (2017) (Liston & Davis, 2017)
Brigatinib	0,9	Bedi <i>et al.</i> (2018) (Bedi <i>et al.</i> , 2018)
Taselisib	0,4	Juric <i>et al.</i> (2017) (Juric <i>et al.</i> , 2017)
AT7519	1,6	Chen <i>et al.</i> (2014) (Chen <i>et al.</i> , 2014)
Momelotinib	4,5	Zheng <i>et al.</i> (2018) (Zheng <i>et al.</i> , 2018)
AZD8055	0,4	Naing <i>et al.</i> (2012) (Naing <i>et al.</i> , 2012)